The Second Affiliated Hospital of Nanjing Medical University

Nanjing 210011

10 studies enrolling now · 20 studies all time

What they study most

Alzheimer Disease, Atherosclerotic Cardiovascular Disease (ASCVD), Cardiovascular Diseases, Chronic Kidney Disease, Diabetes Mellitus, Type 2, Elevated Lp(a), End Stage Kidney Disease, Hypertension, Obesity, Obesity or Overweight, Osteoarthritis, Overweight

Studies at this site

• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease — Recruiting now
• A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight — Recruiting now
• A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin — Recruiting now
• Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight — Recruiting now
• A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes — Recruiting now
• A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes — Recruiting now
• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes — Recruiting now
• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes — Recruiting now
• Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) — Recruiting now
• A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression — Recruiting now
• A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease — Running, not enrolling
• A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight — Completed
• A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes — Running, not enrolling
• A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity — Running, not enrolling
• A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) — Completed
• A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) — Running, not enrolling
• A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes — Running, not enrolling
• A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight — Completed
• A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity — Running, not enrolling
• Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD) — Running, not enrolling